Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dostarlimab + nelistotug
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Dostarlimab + nelistotug** is an investigational combination of two monoclonal antibodies being evaluated as an immunotherapy regimen in oncology. Dostarlimab is an anti-programmed cell death protein 1 (PD-1) monoclonal antibody (marketed as Jemperli), which blocks the PD-1 receptor on T cells, preventing immune evasion by cancer cells. Nelistotug is an experimental monoclonal antibody with a distinct but likely complementary immunomodulatory mechanism. This combination is being studied in clinical trials for advanced solid tumors as part of broader research into checkpoint inhibitor and immune modulating combinations[1][5].
- Brand names
- Jemperli
- Other names
- nelistotug
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD96 (T-cell surface protein tactile)
Beyond the preview
Go deeper on dostarlimab + nelistotug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dostarlimab + nelistotug.